Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug
The first anti-HIV drug, zidovudine (AZT), was approved by the FDA a quarter of a century ago, in 1985. Currently, anti-HIV drug-combination therapies only target HIV-1 protease and reverse transcriptase. Unfortunately, most of these molecules present numerous shortcoming; such as viral resistances...
| Autor principal: | |
|---|---|
| Outros Autores: | , , |
| Formato: | other |
| Idioma: | eng |
| Publicado em: |
2011
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/82028 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/82028 |